Mirk Kinase inhibition blocks the in vivo growth of pancreatic cancer cells

Genes and Cancer

Volumn 5, Issue 9-10, 2014, Pages 337-347

  Deng, Xiaobing ^a   Friedman, Eileen ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

dyrk1B; Kras; Mirk; mTOR; Pancreatic cancer

Indexed keywords

MIRK KINASE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; IN VIVO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPHEROID CELL; SURVIVAL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84927919630     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hruban R, Iacobuzio-Donahue C, Wilentz R, Goggins M, Kern S. Molecular pathology of pancreatic cancer. Cancer J. 2001;7:251-8.
2. Collins MA, Pasca di Magliano M. Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol. 2013;4:407. PMCID: 3896882.
3. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al. Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism. Cell. 2012;149(3):656-70.
4. Jin K, Park S-J, Ewton D, Friedman E. The survival kinase Mirk/dyrk1B is a downstream effector of oncogenic K-ras. Cancer Res. 2007;67:7247-55.
5. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell. 2006;10:241-52.
6. Deng X, Ewton DZ, Friedman E. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by decreasing ROS levels. Cancer Res. 2009;69(8):3317-24.
7. Lauth M, Bergstrom A, Shimokawa T, Tostar U, Jin Q, Fendrich V, et al. DYRK1B-dependent autocrine-toparacrine shift of Hedgehog signaling by mutant RAS. Nat Struct Mol Biol. 2010;17(6):718-25.
8. Kuuselo R, Simon R, Karhu R, Tennstedt P, Marx AH, Izbicki JR, et al. 19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes, Chromosomes and Cancer. 2010;49(6):569-75.
9. Deng X, Ewton DZ, Li S, Naqvi A, Mercer SE, Landas S, et al. The Kinase Mirk/Dyrk1B Mediates Cell Survival in Pancreatic Ductal Adenocarcinoma. Cancer Res 2006;66(8):4149-58.
10. Ewton D, Hu J, Vilenchik M, Deng X, Luk K-C, Polonskaia A, et al. Inactivation of Mirk/dyrk1b kinase targets quiescent pancreatic cancer cells. Mol. Cancer Ther. 2011;10(11):2104-14.
11. Hu J, Deng H, Friedman E. Ovarian Cancer Cells, not Normal cells, are Damaged by Mirk/Dyrk1B kinase inhibition Int J Cancer. 2013;132(10):2258-69.
12. Lee K, Deng X, Friedman E. Mirk Protein Kinase Is a Mitogen-activated Protein Kinase Substrate That Mediates Survival of Colon Cancer Cells. Cancer Res. 2000;60(13):3631-7.
13. Jin K, Ewton D, Park S, Hu J, Friedman E. Mirk regulates the exit of colon cancer cells from quiescence. J Biol. Chemistry. 2009;284(34):22916-25.
14. Zou Y, Ewton D, Deng D, Mercer S, Friedman E. Mirk/dyrk1B Kinase Destabilizes Cyclin D1 by Phosphorylation at Threonine 288. J Biol Chem. 2004;279:27790-8.
15. Janumyan Y, Cui Q, Yan L, Sansam CG, Vanlentin M, Yang E. G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation. J Biol Chem 2008;283:34108-20.
16. Litovchick L, Florens LA, Swanson SK, Washburn MP, DeCaprio JA. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes & Development. 2011;25(8):801-13.
17. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. γH2AX and cancer. Nat Rev Cancer. 2008;8(12):957-67.
18. Lim S, Jin K, Friedman E. Mirk Protein Kinase Is Activated by MKK3 and Functions as a Transcriptional Activator of HNF1alpha. J Biol Chem 2002;277(28):25040-6.
19. Deng X, Ewton DZ, Mercer SE, Friedman E. Mirk/dyrk1B Decreases the Nuclear Accumulation of Class II Histone Deacetylases during Skeletal Muscle Differentiation. J Biol Chem 2005;280(6):4894-905.
20. Casagrande A-S, Bachelot F, Coutadeur S, Leblond B, Besson T, Pando MP, et al. Structure activity relationship of a novel chemical class of Dyrk inhibitors. [abstract] In: Proceeding of the 104th Annual Meeting of the American Association for Cancer Research. 2013;73 (8 Supl) Abstract no.2165. doi:10.1158/1538-7445.AM2013-2165
21. Kinsey C, Balakrishnan V, Äôdell MR, Huang JL, Newman L, Whitney-Miller CL, et al. Plac8 Links Oncogenic Mutations to Regulation of Autophagy and Is Critical to Pancreatic Cancer Progression. Cell Reports. 2014;7(4):1143-55.
22. Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K, et al. The phosphatidylinositol 3- kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther. 2007;6(9):2505-14.
23. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat. 2010;122(1):35-43. PMCID: 2935800.
24. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell. 2012;21(2):227-39. PMCID: 3297962.
25. Deng X, Hu J, Cunningham M, Friedman E. Mirk/Dyrk1B Kinase Inhibition Targets Ovarian Cancer Ascites. Genes & Cancer. 2014;5(5-6):201-11.
26. Pan J, Zhang J, Hill A, Lapan P, Berasi S, Bates B, et al. A kinome-wide siRNA screen identifies multiple roles for protein kinases in hypoxic stress adaptation, including roles for IRAK4 and GAK in protection against apoptosis in VHL-/- renal carcinoma cells, despite activation of the NF- kappaB pathway. J Biomol Screen. 2013;18(7):782-96.
27. Deng X, Ewton D, Hu J, Friedman E. Mirk Kinase is Upregulated Following Inhibition of mTOR. Carcinogenesis. 2014;in press.
28. Correa RJM, Peart T, Valdes YR, DiMattia GE, Shepherd TG. Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids. Carcinogenesis. 2012;33(1):49-58.
29. Hu J, Nakhla H, Friedman E. Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by Mirk/dyrk1B and p130/Rb2 Int J Cancer. 2011;129:307-18.
30. Boichuk S, Parry JA, Makielski KR, Litovchick L, Baron JL, Zewe JP, et al. The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis. Cancer Res. 2013;73(16):5120-9.
31. Sadasivam S, DeCaprio JA. The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer. 2013;13(8):585-95.
32. Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, Howard TJ, et al. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. American J. Surgery. 2003;186(5):486-92.
33. Deng X, Mercer SE, Sun CY, Friedman E. The normal function of the cancer kinase Mirk/dyrk1B is to reduce reactive oxygen species. Genes & Cancer. 2014;5(1-2):22-30. PMCID: 4063251.
34. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003;17(24):3112-26.
35. Fendrich V, Oh E, Bang S, Karikari C, Ottenhof N, Bisht S, et al. Ectopic overexpression of Sonic Hedgehog (Shh) induces stromal expansion and metaplasia in the adult murine pancreas. Neoplasia. 2011;13(10):923-30. PMCID: 3201569.
36. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25(6):719-34.
37. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25(6):735-47.
38. Castellano E, Sheridan C, Thin MZ, Nye E, Spencer-Dene B, Diefenbacher ME, et al. Requirement for interaction of PI3-kinase p110alpha with RAS in lung tumor maintenance. Cancer Cell. 2013;24(5):617-30. PMCID: 3826036.
39. Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F. Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience. Cancer Research. 2013;73(5):1449-53.